Brain Research Centre, UBC Hospital, Vancouver, BC, Canada.
Int J Stroke. 2013 Jul;8(5):348-56. doi: 10.1111/j.1747-4949.2012.00869.x. Epub 2012 Sep 13.
It has been questioned whether patients with cerebral microbleeds are at a greater risk for the development of symptomatic intracerebral hemorrhage following thrombolytic therapy in the management of acute ischemic stroke. Thus far, observational studies have not shown a statistically significant increased risk; however, these have been limited by small sample size. The aim is to better quantify the risk of postthrombolysis intracerebral hemorrhage in patients with acute ischemic stroke and cerebral microbleeds on magnetic resonance imaging. A systematic review of controlled studies investigating the presence of microbleeds on magnetic resonance imaging as a risk factor for intracerebral hemorrhage following thrombolysis in acute stroke patients was conducted. A random effects model meta-analysis was performed. In pooled analysis of five studies totaling 790 participants, the prevalence of microbleeds was 17%. The presence of microbleeds revealed a trend toward an increased risk of postthrombolysis symptomatic intracerebral hemorrhage [odds ratio: 1·98 (95% confidence interval, 0·90 to 4·35; P = 0·09), I(2) = 0%]. Adjusted analysis minimizing potential bias resulted in an increased absolute risk of 4·6% for the development of symptomatic intracerebral hemorrhage in patients with cerebral microbleeds [odds ratio: 2·29 (95% confidence interval, 1·01 to 5·17), I(2) = 0%] reaching borderline significance (P = 0·05). A significant relationship between increasing microbleed burden and symptomatic intracerebral hemorrhage (P = 0·0015) was observed. Isolated analysis of studies using exclusively intravenous tissue plasminogen activator was insignificant. Our data suggest that patients with cerebral microbleeds are at increased risk for symptomatic intracerebral hemorrhage following thrombolysis for acute ischemic stroke. However, current data are insufficient to justify withholding thrombolytic therapy from acute ischemic stroke patients solely of the basis of cerebral microbleed presence.
人们质疑在急性缺血性脑卒中的溶栓治疗中,伴有脑微出血的患者是否发生症状性颅内出血的风险更高。到目前为止,观察性研究并未显示出统计学上显著增加的风险;然而,这些研究受到样本量小的限制。本研究旨在更好地量化磁共振成像显示有脑微出血的急性缺血性脑卒中患者接受溶栓治疗后发生颅内出血的风险。对磁共振成像显示脑微出血作为急性脑卒中溶栓患者发生颅内出血的危险因素的对照研究进行了系统综述。进行了随机效应模型荟萃分析。五项研究共纳入 790 名患者的汇总分析显示,微出血的患病率为 17%。微出血的存在显示出溶栓后症状性颅内出血风险增加的趋势[比值比:1.98(95%置信区间,0.90 至 4.35;P=0.09),I2=0%]。最小化潜在偏倚的调整分析导致伴有脑微出血的患者发生症状性颅内出血的绝对风险增加 4.6%[比值比:2.29(95%置信区间,1.01 至 5.17),I2=0%],达到边缘显著(P=0.05)。观察到微出血负荷与症状性颅内出血之间存在显著关系(P=0.0015)。专门使用静脉注射组织型纤溶酶原激活剂的研究的单独分析无统计学意义。我们的数据表明,伴有脑微出血的急性缺血性脑卒中患者接受溶栓治疗后发生症状性颅内出血的风险增加。然而,目前的数据不足以仅基于脑微出血的存在而拒绝为急性缺血性脑卒中患者进行溶栓治疗。